Her2 Testing: What's Old Is New
Executive Summary
Since the initial approval of Herceptin ten years ago, it has become the poster child for personalized medicine. But for almost as long as the drug has been on the market there have been questions about the diagnostics used with the drug and the degree to which they correlate with clinical response. Spurred by testing guidelines in 2007, there's a new-found focus on the nitty-gritty of laboratory conduct and test concordance that could serve as a useful model for addressing the broad issues of drug-diagnostic convergence.
You may also be interested in...
Delivering Cancer Diagnostics Tools
Pharma is keenly interested in new cancer diagnostics tools, which in many cases are aimed at selecting the best therapy for a specific patient, measuring response to therapy and predicting or more sensitively measuring relapse. These technologies are often the same as those used in pharma's drug development efforts. But deciding with whom and how to ally for the development and distribution of tests is difficult, showing just how uncharted, and bumpy, is the current diagnostics terrain.
Delivering Cancer Diagnostics Tools
Pharma is keenly interested in new cancer diagnostics tools, which in many cases are aimed at selecting the best therapy for a specific patient, measuring response to therapy and predicting or more sensitively measuring relapse. These technologies are often the same as those used in pharma's drug development efforts. But deciding with whom and how to ally for the development and distribution of tests is difficult, showing just how uncharted, and bumpy, is the current diagnostics terrain.
Nanostring Unveils Its Molecular Diagnostics Strategy
One strategy for growth among analytical platform companies is to leverage its instrumentation sales channel by developing or acquiring diagnostics content. Nanostring is now doing this by in-licensing a gene expression signature for breast tumor typing. And unlike other molecular tests for guiding breast cancer therapy, which are performed in specialty CLIA labs run by their developers, this one will be broadly distributed to hospitals and pathology laboratories globally.